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Abstract
Purpose MicroRNAs (miRNAs) play an essential role in
breast malignant tumor development and progression. The
development of clinically validated biomarkers for primary
breast cancer (BC) has remained an insurmountable task
despite other advances in the field of cancer molecular
biology. The objective of this study is to investigate the
differential expression of miRNAs and the potential of
circulating microRNAs as novel primary breast cancer
biomarkers.
Methods Our analyses were performed on 48 tissue and
100 serum samples of patients with primary BC and a set of
20 control samples of healthy women, respectively. The
relative expression of ten candidate miRNAs (miR-106b,
miR-125b, miR-17, miR-185, miR-21, miR-558, miR-625,
miR-665, miR-92a, and miR-93) from the results of four
bioinformatics approaches and literature curation was
measured by real-time quantitative reverse transcription
PCR (qRT-PCR).
Results The level of miR-92a was significantly lower,
while miR-21 was higher, as previous reports, in tissue and
serum samples of BC than that of healthy controls
(p \ 0.001). Logistic regression and receiver operating
characteristic curve analyses revealed the significant and
independent value (p \ 0.001) of the miR-92a and miR-21
expression quantification in serums. Moreover, the
comparison with the clinicopathologic data of the BC
patients showed that decreased levels of miR-92a and
increased levels of miR-21 were associated with tumor size
and a positive lymph node status (p \ 0.001).
Conclusions These findings suggest that many miRNAs
expressions are altered in BC, whose expression profiling
may provide a useful clue for the pathophysiological
research. Circulating miR-92a has potential use as novel
breast cancer biomarker, which is comparable to miR-21.
Keywords Breast cancer  microRNA  miR-92a 
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Introduction
Development of breast malignant tumor is complex mul-
tistep process associated with numerous genetic alterations.
MicroRNAs (miRNAs) are small, non-coding RNA mole-
cules, which modulate expression of target genes and play
essential roles in biological and pathological processes of
diseases (Esquela-Kerscher and Slack 2006). miRNAs
regulate posttranscriptional gene expression depending
upon the complementarities of their sequences with target
mRNAs (Bartel 2004). Kallikrein-related peptidase 5
(KLK5) is a secreted trypsin-like serine protease, encoded
by the human kallikrein gene 5 (KLK5) of the kallikrein
family, under the transcriptional control of estrogens and
progestins (Yousef and Diamandis 1999). It has been
reported that this gene is mainly expressed in breast and
brain (Yousef and Diamandis 1999; Brattsand and Egelrud
1999). The prognostic value of KLK5 expression had
already been demonstrated for BC (Yousef et al. 2002,
2004; Avgeris et al. 2011). In our previous work, we have
confirmed that a statistically significant down-regulation of
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the KLK5 expression levels was observed in the malignant
breast specimens compared with the benign ones.
The diagnostic and prognostic value of KLK5 has already
been demonstrated in BC patients; however, miRNAs
which may regulate KLK5 expression have not been iden-
tified, and whether they can serve as potential biomarkers of
BC is still unclear. In our previous work, hundreds of
miRNAs are predicted by four bioinformatics approaches
including TargetScan Human 5.2, MicroCosm Targets
Version 5, ExprTarget, and MIRANDA (Lewis et al. 2005;
Griffiths-Jones et al. 2008; Gamazon et al. 2010; Lagos-
Quintana et al. 2001). With the results above and literature
curation, ten putative miRNAs (miR-106b, miR-125b, miR-
17, miR-185, miR-21, miR-558, miR-625, miR-665,
miR-92a, and miR-93) are selected to validate. Numerous
publications have been reported that circulating miRNAs
may serve as stable blood-based biomarkers in carcinomas
(Schwarzenbach et al. 2011; Mitchell et al. 2008; Heneghan
et al. 2010). Therefore, we detect the expression levels of
the ten miRNAs in the tissue and serum samples of BC
patients and investigate the potential of circulating
microRNAs as novel primary breast cancer biomarkers.
Methods
Study subjects
Tumor tissues, paired normal adjacent tissues (NATs), and
matching serum samples were collected from 48 cases of
patients with newly diagnosed breast carcinomas. Other
serum samples came from 52 cases of BC patients and 20
cases of healthy controls (HC). All the samples were
recruited at Jinan General Hospital of PLA from January
2009 to December 2011. The clinical stage was classified
according to the American Joint Committee on Cancer
(AJCC) tumor-lymph node-metastasis (TNM) classifica-
tion system. This work was performed according to the
guidelines of Jinan General Hospital of PLA, which abides
by the Helsinki Declaration on ethical principle for medical
research involving human subjects. All subjects gave
informed consent to this work.
Total RNA isolation
The miRNeasy Mini Kit (Qiagen, USA) and mirVana PARIS
Kit (Ambion, USA) were used to isolate the total RNA from
the tissue and serum samples according to the manufacture’s
protocols. RNA quality and quantity were measured by
Lambda Bio UV/VIS Spectrophotometer (PERKIN ELM
ER, USA). The RNA samples were immediately stored at
-80 C or converted into cDNA immediately.
miRNA quantification by qRT-PCR
SYBR green qRT-PCR assay was used for miRNA quan-
tification. In brief, 40–500 ng of RNA containing miRNA
was polyadenylated by poly(A) polymerase and reverse
transcribed to cDNA by One Step PrimeScript miRNA
cDNA Synthesis Kit (TaKaRa, China) according to the
manufacturer’s instructions. Twenty-microliter reverse
transcriptase reactions contained 100 ng total RNA derived
from tissue or 40 ng total RNA form serum, 10 ll
29 miRNA Reaction Buffer Mix (including dNTP Mix-
ture, Mg2? and Universal Adaptor Primer), 2 ll 0.1 %
BSA, 2 ll miRNA PrimeScript RT Enzyme Mix, and
RNase Free dH2O up to 20 ll. The mixture was incubated
at 50 C for 60 min and 85 C for 5 s with XP CYCLER
(BIOER, China).
Real-time quantitative PCR was performed by Roche
LightCycler480 II (Roche, Switzerland) with SYBR
Premix Ex TaqTM II kit (TaKaRa, China). The miRNA-
specific forward primers were designed by Primer Premier
5.0, and the sequences are shown in Table 1. The reverse
primers were provided by the SYBR Premix Ex TaqTM II
kit (Uni-miR qPCR Primer). The reaction was performed at
95 C for 30 s, followed by 40 cycles at 95 C for 5 s and
60 C for 20 s, and then ramped from 65 to 95 C to obtain
the melting curve. RNU6 was assessed as the reference
control for tissue studies, and miR-16 was for serum
studies. The obtained data of miRNA expression levels are
calculated and evaluated by the DCT method as follows:
DCT = Ct(miRNA of interest) - Ct(reference of control).
The relative expression of the target miRNA was calcu-
lated by the method: (1 ? E)(-DCT), E: amplification effi-
ciency. The Ct value was the threshold cycle to detect
fluorescence. Each sample was run in duplicates for
analysis.
Table 1 miRNA-specific forward primer sequences
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Statistical analysis
The statistical analysis was performed by the SPSS software
package, version 17.0 (SPSS Inc. USA). Mann–Whitney U
test, Wilcoxon test, ANOVA, LSD analysis, Spearman-Rho
test, univariate logistic regression analysis, and receiver
operating characteristic (ROC) curves were used in this
work. A p-value \0.05 was considered as statistically sig-
nificant. All p values were two-sided.
Results
miRNAs expression in the tissue samples
of BC and NATs
In the present study, we examined the expression of 10
miRNAs in BC tissues and the paired NATs. With Wilcoxon
test of two dependent variables, miR-185, miR-21, and
miR-93 were significantly overexpressed in the tumor
specimens compared with those in NATs, whereas miR-
125b, miR-558, miR-625, miR-665, and miR-92a were sig-
nificantly down-expressed in BC (p \ 0.01). The expression
of miR-106b and miR-17 in BC tissue samples were not
significantly different from the NATs (p [ 0.05) (Fig. 1).
miRNAs expression in the serum samples
of BC and HC
Preliminary experiments were employed to evaluate the
Ct values of the ten miRNAs in serum samples. Seven
miRNAs including miR-106b, miR-125b, miR-17,
miR-185, miR-558, miR-625, and miR-665 were removed
for low expression with the Ct value about 35. The rest of
the miRNAs including miR-21, miR-92a, and miR-93 were
examined in the serum samples of BC and HC. Consistent
with the aberrant expression in BC tissue samples, miR-21
and miR-92a showed similar pattern of expression change
in serum samples, while miR-93 had no significant differ-
ence between the serum samples of BC and HC. The results
are displayed in Fig. 2.
The relationship between miR-92a and miR-21
expressions and clinical histopathological features
The differences in expression of miR-21 and miR-92a in
NATs, BC tissues of AJCC stage I, II, III were analyzed by
ANOVA and LSD analysis, and the results are shown in
Fig. 3. The relationship between miR-92a and miR-21
expressions and clinical histopathological features was
analyzed by Mann–Whitney U test, and the results are
shown in Table 2. There were no significant differences
between the expressions of the remained miRNAs and
clinical histopathological features. The expressions of the
ten miRNAs have no significant difference among the
patients’ ages (p [ 0.05).
Fig. 1 Expression of miR-92a (a) and miR-21(b) in BC and matched
NATs No. 1–48, (n = 48). AJCC I, No. 1–10 (n = 10); AJCC II,
No. 11–37 (n = 27); AJCC III, No. 38–48 (n = 11). Relative
expression levels of miRNAs were determined by calculating the
ratio between the miRNA and RNU6. c Relative expression levels of
the ten miRNAs in BC and matched NATs are shown as box plots.
The horizontal lines represent the median, the bottom and top of the
boxes represent the 25th and 75th percentiles, respectively, and the
vertical bars represent the range of data. ‘‘filled circle’’ over the 1.5
folds of the interquartile range; ‘‘asterisk’’: over the threefold of the
interquartile range; -DCT = Ct(reference RNU6) - Ct(miRNA of
interest); NS: p [ 0.05; The significant p values of the statistical
evaluations are indicated above the plots
Fig. 2 Expression of miR-21, miR-92a, and miR-93 in BC and HC.
Total RNA derived from the samples of BC (n = 100), and HC
(n = 20) was subjected to qRT-PCR. Relative expression levels were
determined by calculating the ratio between the target and the control
miRNA
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The correlation of miR-21 and miR-92a expression
pattern between BC tissues and paired serums
Spearman-Rho test was carried out to compare the relative
expression of miR-21 and miR-92a in 48 cases of BC tis-
sues and paired serums. The results showed a significant
correlation of miR-21 expression profiles in the tissues with
those in the serums, with r = 0.61 and miR-92a with
r = 0.51 (p \ 0.001).
Estimation of the predictive value of miR-92a
and miR-21 expression regarding the presence of BC
To investigate the predictive value of miR-92a and miR-21
in BC, we measured their expression levels in serum
samples of 100 BC and 20 HC. The results by univariate
logistic regression analysis showed the significant negative
correlation between the miR-92a expression levels and the
risk of a patient to suffer for BC (p \ 0.001). Moreover,
patients with low miR-92a expression levels were at a
higher risk of breast malignancy as compared to those with
high miR-92a expression profiles (HR 0.07); meanwhile,
patients with high miR-21 expression levels were at a
higher risk of breast malignancy as compared to those with
low miR-21 expression profiles (HR 10.07). ROC curve
analyses also showed that both miRNAs could differentiate
BC from HC with an AUC of 0.923 for miR-92a (95 % CI
0.873–0.973) and 0.933 for miR-21 (95 % CI
0.889–0.977), respectively (Fig. 4).
Discussion
miRNAs are small regulatory RNAs involved in various
physiological and pathophysiological processes (Osaki et al.
2008). Recently, miRNAs show great potential as diagnostic
and prognostic biomarkers for BC (Lowery et al. 2008; Iorio
et al. 2005; Blenkiron et al. 2007; Heneghan et al. 2011). In
this work, the levels of ten candidate miRNAs (miR-106b,
miR-125b, miR-17, miR-185, miR-21, miR-558, miR-625,
miR-665, miR-92a, and miR-93) are quantified by qRT-PCR
in tissue and serum samples of patients with BC as well as
HC.
The previous study suggests that miRNAs are stable in
serum by time-course and freeze–thaw cycle analyses and
can escape from RNAse degradation (Schwarzenbach et al.
2011; Mitchell et al. 2008). miRNAs were for the first time
described and detected in the serum of patients with diffuse
B-cell lymphoma in the year 2008 (Lawrie et al. 2008).
Roth et al. (2010) had confirmed that tumor-associated
circulating miRNAs were elevated in the blood of BC
patients and associated with tumor progression. The rela-
tive concentrations of miR-155 in serum significantly dis-
criminated primary BC patients from healthy women,
whereas miR-10b, miR-34a, and miR-155 discriminated
metastatic disease patients from HC. Asaga et al. (2011)
had proved that circulating miR-21 had diagnostic and
prognostic potential in BC. miR-214 was certified as a
diagnostic potential indicator in BC for malignant disease
and metastatic (Schwarzenbach et al. 2012). Because the
serum samples could be easily obtained at different time
points during the course of the disease and the circulating
miRNAs could be quantified by qRT-PCR (Kroh et al.
2010), circulating miRNAs as novel minimally invasive
indicators have important applications in cancer detection.
Serum miRNA is currently limited, due to the fact that
large RNA molecules are detected to be degraded or rela-
tively high Ct values in serum samples. In our work,
miR-106b, miR-125b, miR-17, miR-185, miR-558,
miR-625, and miR-665 have low expression levels with the
Ct values about 35 in serums. Just miR-21, miR-92a, and
miR-93 can be quantified by the qRT-PCR in serum samples.
Fig. 3 Relative expressions of miR-92a (a) and miR-21 (b) in NATs
and BC AJCC stages are shown as box plots. The subjects were
divided into four groups based on the AJCC tumor-lymph node-
metastasis classification system, representing I (n = 10), II (n = 27),
III (n = 11) and NATs (n = 48). -DCT = Ct(reference RNU6)
- Ct(miRNA of interest); NS: p [ 0.05. The significant p values of
the statistical evaluations are indicated above the plots
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miR-21 is one of the most significantly up-regulated
miRNAs in human BC, and its expression had been asso-
ciated with tumor progression and poor prognosis. In our
research, miR-21 is significantly up-regulated in the BC
tissues and serums, and the results indicate a trend for the
association of high miR-21 expression with poor patient
survival. Our results of the miR-21 are consistent with the
prior studies (Asaga et al. 2011; Qian et al. 2009). Studies
have demonstrated that miR-21 functions as an oncogene
by targeting tumor suppressor genes including tropomyosin
1 (TPM1), programmed cell death 4 (PDCD4), and phos-
phatase and tensin homolog (PTEN), leading to cell pro-
liferation and inhibition of apoptosis and regulating cancer
invasion and metastasis in breast cancer (Zhu et al. 2007;
Frankel et al. 2008; Yan et al. 2008).
miR-92a is one of the seven mature miRNAs (miR-17,
miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a)
encoded by the miRNA-17–92 cluster. The miR-17–92
cluster raises first interests after several studies linked the
expression of the cluster to cancer pathogenesis (Mendell
2008). It had been reported that miR-92a promoted lymph
node-metastasis of human esophageal squamous cell car-
cinoma (ESCC) via E-Cadherin (Chen et al. 2011).
Ohyashiki et al. (2011) reported that the expression level of
miR-92a was down-regulated in non-Hodgkin’s lymphoma
(NHL). Plasma miR-92a value in NHL was extremely
lower compared with that in healthy subjects, irrespective
of lymphoma subtype. Tsuchida et al. (2011) determined
that miR-92a was transcribed at a higher level in both
adenomas and carcinoma. miR-92a directly targeted the
anti-apoptotic molecule BCL-2-interacting mediator of cell
Table 2 The relationship
between the relative expression
levels of miR-92a and miR-21
and the clinical
histopathological features








BC 48 0.11–0.21 \0.01 5.30–19.08 \0.01
NATs 48 0.28–0.51 0.79–1.90
Serums
BC 100 0.20–0.37 \0.01 0.32–0.51 \0.01
HC 20 0.50–0.80 0.13–0.19
Tumor size
\2 cm 10 0.10–0.54 \0.01 1.12–11.40 \0.01
C2 cm 38 0.09–0.14 5.11–22.39
Lymph node metastasis
Negative 28 0.13–0.29 \0.01 1.88–9.81 \0.01
Positive 20 0.06–0.10 5.53–36.60
Estrogen receptor
Negative 17 0.08–0.15 [0.05 4.21–20.00 [0.05
Positive 31 0.10–0.26 2.14–22.32
Progesterone receptor
Negative 8 0.04–0.17 [0.05 3.17–36.93 [0.05
Positive 40 0.11–0.23 2.85–18.38
CerbB-2
Negative 39 0.10–0.18 [0.05 3.18–27.22 [0.05
Positive 9 0.07–0.28 3.87–12.76
Fig. 4 miR-92a and miR-21 were plotted to discriminate HC and BC
patients. miR-92a and miR-21 yield an area under the curve (AUC)
value of 0.923 and 0.933, respectively
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death in colon cancer, and they indicated that miR-92a
played a pivotal role in the development of colorectal
carcinoma. Our, hitherto, investigations demonstrate the
cancer-specific decrease in levels of miR-92a. In addition,
the decreased level of miR-92a is also associated with
positive lymph node status, indicating that miR-92a might
be involved in cancer progression. Thus, our findings
suggest that quantification of miR-92a might be suitable for
detecting BC and lymph node metastases. So far, no
investigation of miR-92a has been carried out in blood and
tissue samples from BC patients.
In order to determine the correlation of miRNA
expression in tissue and the matched serum samples, our
results show a significant correlation of miR-21 and
miR-92a expression profiles in the tissues with those in the
serums (Spearman-Rho test r = 0.61 and 0.51, p \ 0.01),
which suggests that miR-21 and miR-92a isolated from
serums could reflect most of the characteristic expression
patterns of their tissue counterparts and further show
promise for miRNAs as blood-based biomarkers for
detecting and screening breast tumors. The univariate
logistic regression model discloses a statistically significant
elevated risk of the patients with reduced miR-92a and
increased miR-21 expression to suffer from BC
(p \ 0.001). As illustrated by the ROC curves with AUC
values of 0.923 for miR-92a and 0.933 for miR-21,
respectively, it suggests that miR-92a and miR-21
expression quantification may be used to discriminate the
BC patients from the HC.
At present, miRNA have become the rising stars in
cancer genetics. miRNAs are excellent candidates for novel
molecular targeting treatments because of their ability to
regulate multiple genes in molecular pathways. Chemo-
therapy is an important component in the treatment para-
digm for cancers. However, the resistance of cancer cells to
chemotherapeutic agents frequently results in the sub-
sequent recurrence and metastasis. Recently, a new data
suggest that the expression level of miR-21 in tumor tissue
and plasma might be used as a biomarker to predict adju-
vant platinum-based chemotherapy response and disease-
free survival in patients with non-small-cell lung cancer.
Thus, it may serve as a novel therapeutic target to modulate
platinum-based chemotherapy (Gao et al. 2012). Wang
et al. (2012) had demonstrated that circulating miR-125b
expression was associated with chemotherapeutic resis-
tance of breast cancer. This finding has important impli-
cations in the development of targeted therapeutics for
overcoming chemotherapeutic resistance in novel antican-
cer strategies. Trastuzumab resistance emerges to be a
major issue in anti-HER2 therapy for breast cancers. Gong
et al. (2011) had demonstrated that miR-21 overexpression
contributes to trastuzumab resistance in HER2? breast
cancers. PTEN was identified as a miR-21 target.
Administering miR-21 antisense oligonucleotides restored
trastuzumab sensitivity in the resistant breast cancer
xenografts by inducing PTEN expression, whereas injec-
tion of miR-21 mimics conferred trastuzumab resistance in
the sensitive breast tumors via PTEN silence. Resistance to
docetaxel also occurred in 50 % of breast cancer patients.
In this work, miRNAs expressions are altered in BC,
whose expression profiling may provide a useful clue for the
pathophysiological research. The expression level of miR-
92a has potential predictive value as novel breast cancer
biomarker in serum samples of BC and correlates with tumor
size and lymph node metastases. The study of miRNAs may
lead to finding their potential for improving diagnosis,
prognosis, and their impact on future therapeutic strategies.
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